Circio Holding ASA — Director's Dealing 2026

May 11, 2026

Circio Holding ASA: Issuance of restricted stock units (RSUs) to board member

Circio Holding ASA: Issuance of restricted stock units (RSUs) to board member

Oslo, 11 May 2026: Reference is made to the annual general meeting of Circio

Holding ASA (the "Company") on 8 May, 2026 (the "AGM") where the election of

members to the board of directors was made according to the proposal by the

nomination committee.

At the AGM, the board of directors was authorized to extend the Company's

restricted stock unit ("RSU") program and to issue RSUs to directors of the

board as an alternative to cash compensation. The RSUs are non-transferable

and each RSU gives the right and obligation to acquire one share in the

Company at a price of NOK 0.60 per share (corresponding to the nominal value

of the shares) subject to satisfaction of the applicable vesting conditions.

If the board members choose to receive the board remuneration in RSUs they

must elect to either (i) receive 100% of the compensation in RSUs, (ii)

receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3

of the compensation in cash and 1/3 in RSUs.

The number of RSUs is calculated on the basis of a board remuneration of NOK

575 000 for the chairperson of the board, NOK 350,000 for other board members

and 180,000 for deputy members of the board, divided by the market price of

the Company's shares calculated as the volume weighted average share price for

the 10 trading days prior to the AGM, on 8 May 2026, being NOK 8.7966 per

share.

* Robert Burns, deputy member of the board of directors, has resolved to

receive 1/3 of the board remuneration, as determined by the Company's annual

general meeting in 2026, in the form of RSUs and the board of directors has

resolved to issue 6,821 RSUs to Robert Burns. Robert Burns holds 6,821 RSUs,

no options and 100,000 shares in the Company.

Please see the attached notifications of trade for information regarding the

issuance of RSUs to the primary insiders.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 50-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.